4
Changes in Ownership
Jade Biosciences, Inc. Filed Acc 0001415889-23-010965
CHIEF SCIENTIFIC OFFICER sold 2,250 shares at an average $17.30 ($38,915)
- CHIEF SCIENTIFIC OFFICER acquired 2,250 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
NIVEN RALPH · CHIEF SCIENTIFIC OFFICER
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2023-07-05 | Exercise or conversion : show line 1 in the form 10b5-1 | +650 | $1.74 | $1,131 | 2,259 | D |
| 2023-07-05 | Exercise or conversion : show line 2 in the form 10b5-1 | +1,600 | $2.14 | $3,424 | 3,859 | D |
| 2023-07-05 | Sale : show line 3 in the form 10b5-1 | −2,031 | $17.23 | $35,002 | 1,828 | D |
| 2023-07-05 | Sale : show line 4 in the form 10b5-1 | −219 | $17.87 | $3,913 | 1,609 | D |
| Open-market sales · 2,250 sh · avg $17.30 · $38,915 | ||||||
Table II: Derivative
5 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2023-07-05 | Exercise or conversion : show line 5 in the form 10b5-1 Stock Option (Right to Buy) | −450 | 18,708 | D |
| 2023-07-05 | Exercise or conversion : show line 6 in the form 10b5-1 Stock Option (Right to Buy) | −200 | 12,088 | D |
| 2023-07-05 | Exercise or conversion : show line 7 in the form 10b5-1 Stock Option (Right to Buy) | −200 | 13,894 | D |
| 2023-07-05 | Exercise or conversion : show line 8 in the form 10b5-1 Stock Option (Right to Buy) | −650 | 42,108 | D |
| 2023-07-05 | Exercise or conversion : show line 9 in the form 10b5-1 Stock Option (Right to Buy) | −750 | 50,732 | D |
Loading xslF345X04/form4-07072023_060701.xml…